MAY 2 7 2003 &

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Index the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 10

Substitute for form 1449A/PTO

required three-points to a contessor or information threes it contains a valid civib contest manager.				
C mplete if Kn wn				
Application Number 09/724,953				
Filing Date	November 28, 2000			
First Named Inventor	Dale B. Schenk			
Art Unit	1647			
Examiner Name	Christopher Nichols			
Attomey Docket Number	15270J-005913US			

U.S. PATENT DOCUMENTS							
		Document Number			·		
Examiner	Cile No. ¹			Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
متحب	340	2002/0162129 A1	10-31-2002	Lannfelt			
	326	2002/0136718 A1	09-26-2002	Raso			
	325	2001/0102261 A1	08-01-2002	Raso			
	306	6,417,178 B1	07-09-2002	Klunk et al.			
	342	2002/0009445 A1	01-24-2002	Du et al.			
	267	6,294,171 B2	09-25-2001	McMichael			
	234	6,284,221 B1	09-04-2001	Schenk, et al.			
	300	2001/0018053 A1	08-30-2001	McMichael	<i></i>		
	230	6,262,335 B1	07-17-2001	Hsiao et al.			
	345	2002/0077288 A1	06-21-2001	Frangione			
	231	6,114,133	09-05-2000	Seubert et al.			
	221	5,989,566	11-23-1999	Cobb et al.			
	346	5,935,927	08-10-1999	Vitek et al.			
	321	5,837,672	11-17-1998	Schenk et al.			
	353	5,824,322	10-20-1998	Balasubramanian			
	357	5,776,468 B1	07-07-1998	Hauser et al.			
I	356	5,622,701	04-22-1997	Berg			
	320	5,593,846	01-14-1997	Schenk et al.			
V	358	5,583,112 B2	12-10-1996	Kensil et al.			
COS	284	5,231,170	07-27-1993	Averback			

	U.S. PATENT DOCUMENTS								
		Document Number							
Examiner	Cite No. ¹	Number Kind Code ² (if known)	Filing Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
600	296	60/254,465	12-08-2000	Holtzman et al.					
	297	60/254,498	12-08-2000	Holtzman et al.					
	305	09/724,842	11-28-2000	Chalifour et al.					
	295	60/184,601	02-24-2000	Holtzman et al.					
	282	60/169,687	12-08-1999	Chain					
	242	60/168,594	11-29-1999	Chalifour et al.					
A	283	09/441,140	11-16-1999	Solomon et al.					
600	299	60/186,295	03-01-2000	Rasmussen et al.					

Examiner Signature	Low	ue S	Date Considered	7/23/2004	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

PA 3307758 vl

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0851-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Kn wn				
Application Number 09/724,953				
Filing Date November 28, 2000				
First Named Inventor Dale B. Schenk				
Art Unit 1647				
Examiner Name	Christopher Nichols			
Attorney Docket Number	15270J-005913US			

FOREIGN PATENT DOCUMENTS								
Examiner	Cite	For	eign Patent Docum	ent		Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code ³	Number ⁴	Kind Code ^s (# known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁸
(3V)	352	wo	02/34777	A1	05-02-2002			-
_1	351	wo	02/34878	A2	05-02-2002			
	343	EP	1 172 378	A1	01-16-2002	,		_
	344	wo	01/90182	A2	11-29-2001			
	348	wo	01/77167	A2	10-18-2001			
	294	wo	01/62801	A2	08-30-2001			Ε.
	298	wo	01/42306	A2	06-14-2001			—
	243	wo	01/39796	A2	06-07-2001			
	341	wo	02/03911	A2	04-07-2001			—
	324	wo	00/72870	A1	12-07-2000			\vdash
19	323	wo	00/72876	A2, A3	12-07-2000			
	322	wo	00/72880	A2, A3	12-07-2000			=
	240	wo	00/43039	A1	07-27-2000			_
	301	wo	01/62284	A2	03-01-2000			\vdash
	331	wo	99/06545	A2	11-02-1999			
4.	187	EP	783 104	A1	07-09-1997			=
600	227	WO	95/11008	A2	04-27-1995			=

Examiner Signature	6 Visoo	Date Considered	2/23/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0851-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

TRADENS Ostitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known				
Applicati n Number 09/724,953				
Filing Dat November 28, 2000				
First Named Inventor	Dale B. Schenk			
Art Unit 1647				
Examiner Name	Christopher Nichols	-		
Attorney Docket Number	15270J-005913US			

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
000	290	YOUNKIN, "Arnyloid & vaccination: reduced plaques and improved cognition," Nature Medicine, 7;18-19 (2001).	
	292	YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," <u>Acta Neuropathol.</u> , 95:217-222 (1998).	
	275	WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," <u>J. Clin. Invest.</u> , 100:1804-1812 (1997).	_
	-223	WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 56. (Publication date unknown:)	
	274	WEINER et al., "Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," <u>Annals of Neurology</u> , 48:567-579 (2000).	
	317	VEHMAS, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. DNA Cell Biol. (11):713 21 (2001).	_
	276	TJERNBERG et al., "Arrest of β-amyloid fibril formation by a pentapeptide ligand," <u>Journal of Biological Chemistry</u> , 271:8545-8548 (1996).	
	273	THORSETT, E.D. and L.H. LATIMER, "Therapeutic approaches to Alzheimer's disease," <u>Curr. Op. in Chem. Biology</u> , 4:377-382 (2000).	
	339	TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," PNAS, 92:4299-4303 (1995).	_
	272	SZENDREI, et al., "The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid β-peptide as modeled with N-terminal decapeptide fragments," Int. J. Peptide Protein Res., 47:289-296 (1996).	
Cot	338	STEIN and JOHNSON, "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," The Journal of Neuroscience, 22(17):7380-7388 (September 1, 2002).	

Examiner Signature	Calling	Date Considered	7/73/14
Oignatare	() (out)	Considered	400

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3307758 v1

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

MAY 2 7 2003 &

PTO/SB/08B (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449B/PTO

Complete if Known

Applicatin Number 09/724,953

Filing Dat November 28, 2000

First Named Inventor Dale B. Schenk

Art Unit 1647

Examiner Name Christopher Nichols

(use as many sheets as necessary)

 Sheet
 4
 of
 10
 Attorney Docket Number
 15270J-005913US

				_
**	ر	271	ST. GEORGE-HYSLOP, PETER H. and DAVID A. WESTAWAY, :Antibody clears senile plaques," Nature, 40:116-117 (1999).	
		316	SOTO, et al. Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med. 4(7):822-6 (1998).	
	_	319	SMALL, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci. 2(8):595-8 (2001).	
		337	SKOLNICK and FETROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <u>Trends in Biotech</u> , 18(1):34-39 (2000).	
		315	SINHA, et al. Recent advances in the understanding of the processing of APP to beta amyloid peptide. Ann N Y Acad Sci. 920:206-8 (2000).	
		314	SIGURDSSON, et al. In vivo reversal of amyloid-beta lesions in rat brain. J Neuropathol Exp Neurol. 59(1):11-17 (2000).	
		330	SIGMUND, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control," <u>Arterioscler Thromb Vasc Biol.</u> , 20:1425-1429 (2000).	
		313	SELKOE, The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8(11):447-53 (1998).	-
		270	SCHENK, et al., "B-peptide immunization," Arch. Nuerol., 57:934-936 (2000).	_
		312	SCHENK, et al. Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. DNA Cell Biol. 20(11):679-81 (2001).	
		277	SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," <u>Brain Res.</u> , 755:193-201 (1997).	
		278	SAITOH, N. and K. IMAI, "Immunological analysis of Alzheimer's disease using anti- β-protein monoclonal antibodies," <u>Sapporo Med. J.</u> , 60:309-320 (1991).	
V		279	SAITO et al., "Vector-mediated delivery of 125 l-labeled β -amyloid peptide Ab $^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the A β $^{1-40}$ vector complex," PNAS USA, 92:10227-10231 (1995).	
0	2	- 304 -	RASO, V.A., Grant application # 1 R43 AGI 5746-01 (non-reducted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).	-

-			
Examiner Signature	6 Mins	Date Considered	2/23/04

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3307758 v1

DO DOT PRINT (NOTATE).

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0851-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

Sheet

TA TRADE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	Compl te if Kn wn	
Applicati n Number	09/724,953	
Filing Dat	November 28, 2000	
First Named Inventor	Dale B. Schenk	
Art Unit	1647	
Examiner Name	Christopher Nichols	
Attorney Docket Number	15270J-005913US	

GNS	269	PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," <u>J. of Neuroscience</u> Res., 46:709-719 (1996).	
	232	PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monocional Antibodies," <u>Laboratory Animal Science</u> , 46(1):8-14 (1996).	-
	336	PERUTZ et al., "Amyloid fibers are water-filed nanotubes," PNAS, 99(8):5591-5595 (2002).	
	280	PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem, Biophys. Res. Comm.</u> , 146:307-313 (1987).	
	329	NIEMANN, "Transgenic farm animals get off the ground;" <u>Transgenic Research</u> 7:73-75 (1998).	_
	350	Nicoll et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid-β peptide: a case report," Nature Medicine, 9(4):448-452 (April 2003).	
	235	NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," <u>Biochim. Biophys.</u> <u>Acta</u> , 104:480-486 (1965).	
	281	NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," <u>J. of Med. Primatology</u> , 27:244-252 (1998).	
	268	NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein (Aβ) subtypes (Aβ40 and Aβ42(43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," Neuroscience Letters, 201:151-154 (1995).	
	250	NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomologus monkeys," Exp. Anim., 43:711-718 (1995).	
	354	MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects," (1995) 7, 11-12, medpharm Scientific Publishers, Stuttgart, Germany.	
	355	MUNSON ed., "Principals of Pharmacology: Basic Concepts & Clinical Applications," (1995), 47-48, Chapman & Hall, New York, New York.	
V	359	MUNCH et al., "Potentional neurotoxic inflammatory response to Aβ vaccination in humans," (2002) <u>J.</u> <u>Neural Transm.</u> , 109:1081-1087.	
CN	233	MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," Neurology, 39:1159-65 (1989).	

|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include/copy of his form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3307758 v1

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Kn wn

Applicatin Number 09/724,953

Filing Date November 28, 2000

First Named Inventor Dale B. Schenk

Art Unit 1647

Examiner Name Christopher Nichols

Attorney Docket Number 15270J-005913US

(use as many sheets as necessary)

		•	
cos	311	MORGAN, et al., "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," Nature. 408(6815):982-5 (2000).	
	310	MERLUZZI, et al. Humanized antibodies as potential drugs for therapeutic use. Adv Clin Path. 4(2):77-85 (2000).	
	265	MENA, et al., "Monitoring pathological assembly of tau and $β$ -amyloid proteins in Alzheimer's disease," Acta Neuropathol., 89:50-56 (1995).	
	238	MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," <u>Virology</u> , 243:158-166 (1998).	
	264	MCGEER, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," <u>J. of Neuroscience Res.</u> , 31:428-442 (1992).	
	309	MATTSON, Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev. 77(4):1081-132 (1997).	
	335	MASLIAH et al., *β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease,* PNAS, 98(21):12245-12250 (2001).	_
	262	MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," Neuroscience Letters, 196:105-108 (1995).	
	263	MANN, et al., "Amyloid β protein ($A\beta$) deposition in chromosome 14-linked Alzheimer's disease: Predominance of $A\beta_{42(43)}$," Annals of Neurology, 40:149-156 (1996).	
	261	MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," Brain Research, 667:138-142 (1994).	
	260	LEMERE, et al., "Nasal A& treatment induces anti-A& antibody production and decreases cerebral amyloid burden in PD-APP mice," <u>Annals of the NY Acad. Sci.</u> , 920:328-331 (2000).	
	259	LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," Curr. Ops. In Chemical Biology. 1:260-267 (1997).	
(2)	258	KIDA, et al., "Early amyloid-β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," Neuroscience Letters, 193:105-108 (1995).	

Examiner Signature	(2 U)	Date Considered	2	23/04	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3307758 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

TRADEN Obstitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	C mplete if Known
Application Number	09/724,953
Filing Date	November 28, 2000 .
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	15270J-005913US

(ည	347	JORBECK et al., "Artificial Salmonella Vaccines: Salmonella typhimurium O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," Infection and Immunity, May:497-502 (1981).	
		334	JOBLING and HOLMES, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," Molecular Microbiology, 5(7):1755-1767 (1991).	
		257	JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," <u>Brain Research Protocols</u> , 2:23-30 (1997).	1
		308	JANUS, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408(6815):979-82 (2000).	-
		256	IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzhelmer's disease with an anti-β protein monoclonal antibody," <u>Lab. Invest.</u> , 57:446-449 (1987).	_
		236	HILBICH.et al., :Human and rodent sequence analogs of Alzheimer's amyloid \$A4 share similar properties and can be solubilized in buffers of pH 7.4,* <u>Eur. J. Biochem.</u> , 201:61-69 (1991).	
		229	HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2", Immunology, Vol. 78: 643-649 (1993).	
		25 5	HARIGAYA, et al., "Modified amyloid \$\beta\$ protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," Biochem. Biophys. Res. Comm., 211:1015-1022 (1995).	
		241	HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," Nature, 359(6393):322-5 (1992).	
		254	GRUBECK-LOEBENSTEIN, et al., "Immunization with β-amyloid: could T-cell activation have a harmful effect?", <u>TINS</u> , 23:114 (2000).	
		237	GORTNER, <u>Outlines of Biochemistry</u> , pp. 322-323, John Wiley & Sons, Inc., New York (1949).	
V	,	303	GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," lmmunology , 93:149-153 (1998).	_
CI	2	253	GIULIAN, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <u>Journal of Biological Chem.</u> , 273:29719-29726 (1998).	_

Examiner Signature Date Considered 2/23/04	Considered 2//3/()
--	--------------------

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference/considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Co	
09/724,953	
November 28, 2000	
Dale B. Schenk	
1647	
Christopher Nichols	
15270J-005913US	
	Dale B. Schenk 1647 Christopher Nichols

ی	صو	252	GEDDES, "N-terminus truncated β-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," Neurobiology of Aging, 20:75-79 (1999).	_
		251	GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Blochem, Blophys, Res, Comm.</u> , 173:1292-1298 (1990).	
		249	FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in <u>Cerebrovascular Pathology</u> in <u>Alzheimer's Disease</u> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).	
		244	FRENKEL, et al., "Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single chain antibody," <u>J. of Neuroimmunology</u> , 106:23-31 (2000).	
		248	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β -amyloid peptide represents the epitope of its anti-aggregating antibodies," <u>J. of Neuroimmunology</u> , 88:85-90 (1998).	
		247	FRENKEL et al., "Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration," <u>PNAS USA</u> , 97:11455-11459 (2000).	
		245	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation," J. of Neuroimmunology, 95:136-142 (1999).	
		246	FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <u>Vaccine</u> , 19:2615-2619 (2001).	
		328	FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing;" <u>Alzheimer's and Parkinson's Diseases</u> , Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995).	_
		289	ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," <u>Trends In Pharm. Sci.</u> , 22:2-3 (2001).	_
		226	Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002)	
	/	225	Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/28/2002).	
0		288	OUMERY et al., "β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," Pathol. Biol., 49:72-85 (2001).	

Examiner Signature	/ Nilos	Date Considered	2/23/01
-3			

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3307758 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

7 2 7 2003 &

PTO/SB/08B (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Kn wn

09/724,953

Under the Paperwork Raduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Application Number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Filing Date November 28, 2000

First Named Inventor Dale B. Schenk

Art Unit 1647

Examiner Name Christopher Nichols

(use as many sheets as necessary)

Sheet 9 of 10 Attorney Docket Number 15270J-005913US

$\overline{}$					i
<u> </u>	SW	318	DU, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 57(5):801-5 (2001).	_	(F)
		220	Dialog/Derwent, Abstract of WPI Acc No: 1997-054436/199706: Stable vaccine compens. — comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a.water ect. ergenic solvent and saline or water, Derwent File 351: Derwent WPI database. (Publication date unknown.)		NOVATE
		293	DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," <u>Life Scl.</u> , 63:2121-2131 (1998).		_
		287	COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand. J. J. Immunol.</u> , 38:177-182 (1993).		R/N
		286	CORDELL, B., "β-Amyloid formation as a potential therapeutic target for Alzheimer's disease," <u>Ann.</u> <u>Rev. Pharmacol. Toxicol.</u> , 34:69-89 (1994).		1
		333	CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," PNAS, 97(2):571-576 (2000)		5
ï		291	COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," Pharm. Res., 17:266-274 (2000).		6
		302	CHUNG et al., "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β-Peptide by Microglial Cells," <u>J. Biol. Chem</u> ., 274(45):32301-32308 (1999).		
		307	CHEN et al., A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 408(6815):975-9 (2000).		27
		332	CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice," <u>Progress in Brain Research,</u> Van Leeuwen et al. Eds, 117:327-337 (1998).		Shi
		-222	Chemical Abstract database, Abstract of "injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (Publication date unknown:)		かり
J	/	349	CHECK, "Battle of the Mind," Nature, 422:370-372 (March 2003).		
Ć	W	266	CHAPMAN, PAUL F., "Model behavior," <u>Nature</u> , 408:915-916 (2000).		-
					4

Examiner Signature	1/1/00	Date Considered	2/23/04

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3307758 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional), ² Applicant is to place a check mark here if English language Translation is attached.

-

PTO/SB/08B (10-01)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 09/724,953

Filling Date November 28, 2000

First Named Inventor Dale B. Schenk

Art Unit 1647

Examiner Name Christopher Nichols

Attorney Docket Number 15270J-005913US

(use as many sheets as necessary)

 Sheet
 10
 of
 10
 Attorney Docket Number
 15270J-005913US

GN	224	Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thirnerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : http://www.fda.gov/cber/vaccine/thirnerosal.htm, last updated May 16, 2002.	_
	285	CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <u>Clin, Neuropharm.</u> , 15:414A-414B (1992).	
	327	CAMERON, "Recent Advances in Transgenic Technology," Molecular Biotechnology, 7:253-265 (1997).	
A	239	BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET.	-
CN	228	BARROW, et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" <u>J. Mol.Biol.</u> , 225(4): 1075-1093 (1992).	

Examiner Signature	Miss	Date Considered	7/23/04
			21971-

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3307758 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

MAY 2 7 2003 &

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known				
Application Number	09/724,953			
Filing Date	November 28, 2000			
First Named Inventor	Dale B. Schenk			
Art Unit	1647			
Examiner Name	Christopher Nichols			
Attorney Docket Number	15270J-005913US			

		Document Number			
Examiner	Cile No. ¹	Number Kind Code ² (if known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
			U.S. PATENT DOCUM	ENTS	
		Document Number			
	Cite	Number Kind Code ² (if known)	Filing Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant

LLC DATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Forei	gn Patent Doo	cument	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code ³	Number ⁴	Kind Cods [‡] (if known)	Date MM-DD- YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T°

			<u> </u>
Examiner Signature	[Will	Date Considered	2/23/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

OIPE TO

PTO/SB/08B (10-01)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Statute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 09/724,953

Filing Date November 28, 2000

First Named Inventor Dale B. Schenk

Art Unit 1647

Examiner Name Christopher Nichols

Attorney Docket Number 15270J-005913US

(use as many sheets as necessary)

Sheet 2 of 2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials * No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

T 2 Nicoll et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid-β peptide: a case report," Nature Medicine, 9(4):448-452 (April 2003).

Examiner Signature	/	Vie	Date Considered	2/23/04	
	7				

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO	Complet if Known	RECFI
Under the Paperwork Reduction Act of 1995, no persons a	re required to respond to a collection of information unless it contains a val	id OMB control number.
	U.S. Patent and Trademark Office: U.S. DEPARTME	
	Approved for use through 10/31/20	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

_	Complet if Known
Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1646- 1647 TECH CENT
Examiner Name	Unassigned Nicros CH CENT
Attorney Docket Number	15270J-005910US

lease type a plus sign (+) inside this box

heet

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known 09/585,817 **Application Number** INFORMATION DISCLOSURE Filing Date June 1, 2000 STATEMENT BY APPLICANT Schenk, Dale B. First Named Inventor 1640- 1647 Group Art Unit (use as many sheets as necessary) **Examiner Name** Unassigned Sheet of 15270J-005910US Attorney Docket Number

	→ .S. PATENT DOCUMENTS							
		U.S. Patent Document				Pages, Columns, Lines,		
Examiner Initials *	Cite No.1	Number	Kind Code ² (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear		
	AA							
	AB							
	AC							
***	AD							
	AE							
	AF							
	AG							
	AH	·						
	Al							
	LA							
	AK							
	AL							
	AM			<u> </u>				
	AN							
	AO							
	AP							
	AQ							
	AR							
	AS	l		l				

		7	
Examiner Signature	1/1/19	Date Considered	2/23/04
<u> </u>	1,2/1/1/2		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number

Substitute	for form 1449B/P	то	Complete if Known			
		L DIGGL COURT	Application Number	09/585,817		
		N DISCLOSURE	Filing Date	June 1, 2000		
STAT	LEWENT I	BY APPLICANT	First Named Inventor	Schenk, Dale B.		
			Group Art Unit	1046-1647		
	(use as many s	heets as necessary)	Examiner Name	Unassigned Nichels		
Sheet	3	of	Attorney Docket Number	15270J-005910US		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the T 2 Cite Examiner item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue No.1 Initials * number(s), publisher, city and/or country where published. вс BD BE BE BG 8H ВІ BJ ВK BL вм

Examiner	2115	Date	7/22/24
Signature	12000	Considered	<u> 1123107</u>

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3172864 v1



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Sheet

OCT

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necosary) 10

Complete if Known				
Application Number	09/724,953			
Filing Date	November 28, 2000			
First Named Inventor	Schenk, Dale B.			
Group Art Unit	1647			
Examiner Name	Unassigned Nichols			

15270J-005913US Attorney Docket Number

۱	U.S. COTENT DOCUMENTS								
1			\\rightarrow	U.S. STENT DOCUMENTS					
1	C Raminer 0	220	U.S. Patent Doo Number Kind C		ADEMANTA ADEMANTA OF Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
١	700	196	6,150,091		Pandolfo et al.	11-21-2000			
1	278	1	6,057,367		Stamler et al.	05-02-2000			
1	PAUL	2	5,958,883		Snow	09-28-1999			
	200	3	5,955,317		Suzuki et al.	09-21-1999			
	200	4	5,955,079		Mond et al.	09-21-1999			
ı	4	5	5,877,399		Hsiao et al.	03-02-1999			
1	600	6	5,869,093		Weiner et al.	02-09-1999			
	230	7	5,869,054		Weiner et al.	02-09-1999			
	CODO	8	5,854,204		Findeis et al.	12-29-1998			
1	200	9	5,851,998		Kline	12-22-1998			
1	200	10	5,849,298		Weiner et al.	12-15-1998			
ł	C300	11	5,837,473		Maggio e al.	11-17-1998			
	200	12	5,786,180		Konig et al.	07-28-1998			
ı	670	207	5,780,587		Potter	07-14-1998			
	477 0	13	5,753,624		McMichael et al.	05-19-1998			
Ì	(J)	14	5,750,349		Suzuki et al.	05-12-1998			
	4	197	5,744,368		Goldgaber et al.	04-28-1998			
	6	211	5,736,142		Sette et al.	04-07-1998			
	3	15	5,733,547		Weiner et al.	03-31-1998			
	S	16	5,688,651		Solomon	11-18-1997			
	233	17	5,679,348		Nesburn et al.	10-21-1997			
	3	18	5,645,820		Hafler et al.	07-08-1997			
	(1)	19	5,641,474		Hafler et al.	08-24-1997			
	دى	20	5,641,473		Hafler et al.	06-24-1997			
	ري	21	5,612,486		McConlogue et al.	03-18-1997			
	(AD)	22	5,605,811		Seubert et al.	02-25-1997			
	₹.	23	5,585,100		Mond et al.	12-17-1996			
	777	24	5,571,500		Hafler et al.	11-05-1996			
	8	25	5,571,499		Hafler et al.	11-05-1996			
	<u> </u>	175	5,441,870	-	Seubert, et al.	08-15-1995			
	(D)	26	5,434,170	_	Andrulis, Jr.	07-18-1995 02-07-1995			
	600	27	5,387,742		Cordell Van Nostrand et al.	12-14-1993			
	رهي	181	5,270,165			07-27-1993			
-	روي	28	5,231,000		Majocha et al.	06-15-1993			
	رىء	29	5,220,013		Ponte et al.	05-04-1993			
	محت	30	5,208,036		Eppstein et al.	03-09-1993			
	CAN	31	5,192,753		McGeer et al.	03-08-1883			

Examiner Signature	(- Min 100	Date Considered	11/15/02
<u> </u>			

'EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

OCT

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO **Application Number** 09/724,953 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT Schenk, Dale B. First Named Inventor **Group Art Unit** (use as many sheets as necessary) Unassigned **Examiner Name** 15270J-005913US Attorney Docket Number

02-16-93 5,187,153 Cordell et al. 5,057,540 Kensil et al. 10-15-1991 04-0201991 5,004,697 Pardridge 05-19-1987 4,666,829 Glenner et al.

OSMA'Z								
				FOREIGI	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Fore Office ³	eign Patent Doo Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	, T ⁶
C27/2	35	EP	911 036	A2		04-28-1999		
(2)	36	EP	868 918	A2		10-07-1998		
تعري	37	EP	863 211	A1		09-09-1998		
لاق	38	EP	845 270	A1		06-03-1998		
ক্ষ	39	ΕP	782 859	A1		07-09-1997		
درود	40	EP	683 234	A1		11-22-1995		
433	41	EP	666 080	A1		08-09-1995		
200	42	EP	652 962	B1		12-16-1998		
C5X	43	EP	639 081	B1		11-03-1999		
CO		EP	613 007	A2		08-31-1994		
CON	45	EP	594 607	B1	-	08-27-1997		
حاك	46	EP	561 087	B1		08-04-1999		
732	47	EP ·	526 511	B1		05-28-1997		ļ
دري	48	EP	506 785	B1		03-15-2000		
CRS	49	EP	451 700	A1		10-16-1991		
دري	50	EP	440 619	B1		01-24-1996		
200	51	EP	359 783	B1		11-29-1995		
6N	52	EP	276 723	B1		12-08-1993		Yes
	487		783 101			07 00 1007		
(220	199	PCT	00/77178	A1		12-21-2000		-
دکار	188	PCT	00/43049	A1		07-27-2000		-
4500	53	PCT	99/60024	A1		11-25-1999		
420	54	PCT	99/60021	A2		11-15-1999		-
(30)	55	PCT	99/58564	A1		11-18-1999		
C37	56	PCT	99/06066	A2		02-11-1999		-
CPU	57	PCT	99/27949	A1		06-10-1999		-
(28)	58	PCT	99/27944	A1		06-10-1999		
رى	59	PCT	99/27911	A1		06-10-1999		<u> </u>
4	203	PCT	99/00150	A2		01-07-1999		-
250	60	PCT	98/44955	A1		10-15-1998		
ZQL'	61	PCT	98/07850	A2		02-26-1998		

Date Examiner Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3173244 v1

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Sheet

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT (use as many sheets as necessary)

09/724,953	
November 28, 2000	
Schenk, Dale B.	
1647	
Unaccigned Nichols	
15270J-005913US	

										ے
Λ	PEN	202	PCT	97/21728	A1 '		06-19-1997			
'	430	62	PCT	97/17613	A1		05-15-1997			l
	403	63	PCT	96/39176	A1		12-12-1996 .			1
r d	3 2000	208	PCT:	96/28471	A1 .		09-19-1996			ı
	4504	64	PCT	96/25435	A1		08-22-1996			1
	C779	65	PCT	96/18900	A1 .		06-20-1996			i
70	1027150	66	PCT	95/31996	A1		11-30-1995			í
13	200	200 ·	PCT	95/12815	A1		05-11-1995			İ
	CIE	67	PCT	95/11994	A1		05-04-1995			1
	CN	68	PCT	95/11311	A1		04-27-1995			l
	CD	69	PCT	95/05853	A1.		03-02-1995			l
	202	70	PCT	95/04151	A2		02-09-1995			l
	630	201	PCT	94/28412	A1		12-08-1994		•	ĺ
	COD	71	PCT	94/03615	A1		02-17-1994		-	ĺ
	CN)	72	PCT	94/01772	A1		01-20-1994	~	1	l
	CPS	73	PCT	93/21950	A1		11-11-1993			ĺ
	433	74	PCT	93/16724	A1		09-02-1993			ĺ
	دري	75	PCT	93/15760	A1		08-19-1993			İ
	(2)	76	PCT	93/14200	A1		07-22-1993			i
	کوی	205	PCT	93/04194	A1		03-04-1993			İ
	CITU	77	PCT	93/02189	A1		02-04-1993			ı
	لاحك	78	PCT	92/13069	A1	,	08-06-1992			İ
	270	79	PCT	92/06708	A1		04-30-1992			İ
	630	80	PCT	92/06187	A1		04-16-1992			i
	C30	81	PCT	91/19810	A1		12-26-1991			ı
	C84	82	PCT	91/16819	A1		11-14-1991			ĺ
	CRU	83	PCT	91/12816	A1		09-05-1991			ı
	3	84	PCT	91/08760	A1		06-27-1991			ı
	2	85	PCT	90/12871	A1		11-01-1990			—
	272	86	PCT	90/12870	A1		11-01-1990			ľ
	E C	87	PCT	89/01343	A1		02-23-1989		~	ı
	3	88	PCT	89/06242	A1		07-13-1989			ı
	4	89	PCT	89/06689	A1		07-27-1989			l
	9	90	PCT	89/03687	A1		05-05-1989		7	ı
	CIP	91	PCT	88/10120	A1		12-29-1988		7	ı
	دى	92	GB	2 220 211	Α		01-04-1990		<u> </u>	ı
	C S	93	GB	2 335 192	Α		09-15-1999			

		0.00	
Examiner Signature	Mila	Date Considered	11/15/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Known				
Application Number	09/724,953			
Filing Date	November 28, 2000			
First Named Inventor	Schenk, Dale B.			
Group Art Unit	1647			
Examiner Name	Unassigned Nichols			
Attomey Docket Number	15270J-005913US			

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS								
	Examiner Initials •	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ².					
	432	94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," Neurology. 45:1441-1445 (1995).	-					
١	(2)	95	Associated Press, "Immune cells may promote Alzehimer's, a study finds," The Boston Globe (4/13/95).						
cd	1 22 3001	€ 4 30	BAUER et al., "Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <u>FEBS Letters</u> , 285(1):111-114 (1991).	-0-					
8	THAT TO SE	204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor- Transgenic Mice," <u>Eur. J. Immunol</u> , 29:345-354 (1999).						
	600	212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheomer's Diseases," Soc. for Neuroscience Abstracts 18:764 (1992).	_					
	دوي	176	BARD et al., "Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," Nature Medicine, 6(8):916-919 (2000).	-					
	ريون	97	BLASS, John P., "Immunologic Treatment of Alzheimer's Disease," New England J. Medicine, 341(22):1694 (1999).	_					
	620	98	BODMER et al., "Transforming Growth Factor-Bela Bound to Soluble Derivatives of the Bela Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem. Biophys. Res. Comm.</u> , 171(2):890-897 (1990).	-					
	ريهن	99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <u>Neuron</u> , 19: 939-945 (1997).						
	ىتى	100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <u>Cur. Opin. Genet Develop.</u> , 3: 102-109 (1993).	-8-					
	con	101	BRICE et al., "Absense of the amyloid precursor protein gene mutation (APP717 : Val->lle) in 85 cases of early onset Alzheirner's disease," <u>J. Neurology, Neurosurg. Psychiatry</u> , 56:112-115 (1993).	-0-					
	(2)	102	CHAO et al., "Transforming Growth Factor-β Protects human Neurons Against β-Amyloid-Induced Injury," <u>Soc. Neurosci. Abstracts</u> , 19:513.7 (1993).	4					
	Coss	213	CHEN et al. "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," Neuroscience Letters 125:223-226 (1991).						
	دى	214	DEMATTOS et al., "Peripheral Anti Aβ Antibody Alters CNS And Plasma Aβ Clearance and Decreases Brain Aβ Burden in a Mouse Model of Alzheimer's Disease," Proc. Natl. Acad. Sci. USA, 10.1073/pnas.151261398 (2001).	_					
	ديرب	103	DUFF et al., "Mouse model made," Nature, 373: 476-477 (1995).						

Examiner Signature	Collins	Date Considered	11/15/02

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3173244 v1

EXAMINER: Initial if reference considered, whether ocnot citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031*
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO 09/724,953 **Application Number** INFORMATION DISCLOSURE **Filing Date** November 28, 2000 STATEMENT BY APPLICANT Schenk, Dale B. First Named Inventor Group Art Unit 1647 (use as many sheets as necessary) **Examiner Name** Unassigned Dichols 15270J-005913US Sheet Attorney Docket Number

-	100			
4	8	C104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neurol.</u> <u>Sciences</u> , 59:341-347 (1983).	_
00		A 105	FELSENSTEIN et al., "Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," Neuroscience Letters, 152:185-189 (1993).	
	The Mary	106	FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," Neurobiology of Aging, 17(5):809-815 (1996).	
,	رى	107	FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," PNAS, 88:1779-1782 (1991).	
	دى	108	FLANDERS et al., "Altered expression of transforming growth factor-β in Alzhelmer's disease," Neurology, 45:1561-1569 (1995).	
	دروي	210	FRIEDLAND et al., "Development of an anti-Aβ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," Mol. Neurology, 9:107-113 (1994).	
	ده	109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein," <u>Nature</u> , 373(6514): 523-527 (1995).	
	دوي	215	GAMES et al., *Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with Aβ ₁₄₂ ,* <u>Annals of</u> the New York Academy of Science 920:274-84 (2000).	
	ده	110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TiPS</u> , 13:108-113 (1992).	
	دى	111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.,</u> 177:1181-1186 (1993).	
	CON	112	GLENN et al., "Skin immunization made possible by cholera toxin," Nature, 391: 851 (1998).	_
	(N)	113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochemical and Biophysical Research Communications</u> , 120(3): 885-890 (1994).	
	CON	114	GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochemical and Biophysical Research Communications</u> , 122(3): 1131-1135 (1984).	
	رس	115	—GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," Nature, 349:704-708 (1991).	
	(SW)	116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," PNAS, 93:427-432 (1996).	_
	دي	190	GRAVINA et al., "Amyloid β Protein (Αβ) in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13):7013-7016 (1995).	-
	رك	117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diptheria toxin in mice and guinea pigs and their implications on the development and control of diptheria vaccine based on CRMs," Vaccine, 15(12/13): 1341-1343 (1997).	_
	Cyc	118	HAGA et al., "Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Research</u> , 601:88-94 (1993).	_

Examiner Signature	CMM . Com	Date Considered	11/15/07
Signature	VY / Warley	Considered	1110102

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3173244 v1

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

TECH CENTER 1600/2900

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	te for form 1449A/PT	o		Complete if Known		
				Application Number	09/724,953	
INFO	PRMATION	DIS	CLOSURE	Filing Date	November 28, 2000	
STA	TEMENT B	ΥΑ	PPLICANT	First Named Inventor	Schenk, Dale B.	
•				Group Art Unit	1647	
	(use as many sh	eets as	necessary)	Examiner Name	Unassigned Ni dools	
Sheet	6	of	10	Attorney Docket Number	15270J-005913US	

_				
	S. T. S.	119	HANES et al., "New advances in microsphere-based single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: 97-119 (1997).	
2C/	WIN .	발 120	HARDY, "Amyloid, the presentlins and Alzheimer's disease," TINS, 20(4): 154-159 (1997).	
	CON S	121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28:255-258 (1998).	-
9	CON	193	HARRINGTON et al., "Characterisation of an epitope specific to the neuron-specific isoform of human enclase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," Biochimica Biophysica Acta, 1158:120-128 (1993).	
	EM)	177	HELMUTH, L., "Further Progress on a β-Amyloid Vaccine," <u>Science</u> , 289:375 (2000).	
	SIN	122	HSIAO et al., "Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice," <u>Science</u> , 274: 99-102 (1998).	
	EBU	123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J. Neuroimmunology</u> , 52:147-152 (1994).	
	(m)	124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," N. E. J. Medicine, 333(19):1283-1284 (1995).	
	CDN	125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J.</u> <u>Neuroimmunology</u> , 24:173-182 (1989).	_
	SW	192	IWATSUBO et al., "Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species Is Aβ42(43)," <u>Neuron</u> , 13:45-53 (1994).	
	ಈ	126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," Immun. Rev., 62: 185-216 (1982).	_
	9	S 216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," Am. J, of Pathology 138:373-378 (1991).	
	600	127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," Res. Immunology. 143:637-641 (1992).	
	600	183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <u>Biotechnol. Appl. Biochem.</u> , 23:227-230 (1996).	_
	روع	128	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," Nature, 354:476-478 (1991).	
	GN	195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl- Terminus of the βA4 Peptide," <u>Annals of NY Acad, Sci.</u> , 777:344-355 (1998).	_
	GN	129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," Neurodegeneration, 2:111-121 (1993).	
	90	130	LANGER, "New Methods of Drug Delivery," Science, 249: 1527-1532 (1990).	
			A	

Examiner Signature	Mins	Date Considered	1]	15102

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3173244 v1

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 09/724,953 INFORMATION DISCLOSURE November 28, 2000 STATEMENT BY APPLICANT Schenk, Dale B. First Named Inventor 1647 Group Art Unit Nichols

(use as many sheets as necessary) Examiner Name Unassigned 15270J-005913US Attorney Docket Number Sheet

LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain Res.</u> 57:207-213 (1993). LEMERE et al., "Mucosal Administration of AP Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice," <u>Society for Neuroscience Abstracts</u> , vol. 25, part I, Abstract 519.6, 29th Annual Meeting, (October 23-26, 1999). LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <u>J. Immunol.</u> , 159: 1383-1392 (1997). LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <u>Acta. Neurol. Scand.</u> , 84:441-444 (1991). MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy." <u>The J. of Nuclear Med.</u> 33:2184-2189 (1992). MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <u>Proc. Natl. Acad. Sci. USA.</u> 82:4245-4249 (1985). MCGEE et al., "The encapsulation of a model protein in poly (D. L lactide-co-glycolida) microparticles of various sizes: an evaluation of process reproducibility." <u>J. Micro. Encap.</u> , 14(2): 197-210 (1997). MEDA et al., "Activation of microglial cells by β-amyloid protein and interferon-γ." <u>Nature</u> , 374:647-650 (1995). MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens." <u>J. Exp. Med.</u> , 174:791-798 (1991). MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am. J. Pathology</u> , 144(5):1082-1088 (1994). NATHANSON et al., "Bovine Spongiform Encaphalopathy (BSE): Causes and Consequences of a Common Source Epidemic." <u>Am. J. Epidemiol.</u> , 145(11): 959-969 (June 1, 1997).	
Mice, "Society for Neuroscience Abstracts, vol. 25, part I, Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999). LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," J. Immunol., 159: 1383-1392 (1997). LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," Acta. Neurol. Scand., 84:441-444 (1991). MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," The J. of Nuclear Med. 33:2184-2189 (1992). MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," Proc. Natl. Acad. Sci. USA 82:4245-4249 (1985). MCGEE et al., "The encapsulation of a model protein in poly (D. L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," J. Micro. Encap., 14(2): 197-210 (1997). MEDA et al., "Activation of microglial cells by β-amyloid protein and interferon-γ," Nature, 374:647-650 (1995). MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J. Exp. Med., 174:791-798 (1991). MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," J. Biol. Chem., 267(24):17082-17088 (1992). MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994).	Ⅎ
Are Comparable to Those Eticited by Acute Viral Infection," J. Immunol., 159: 1383-1392 (1997). LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," Acta. Neurol. Scand., 84:441-444 (1991). MAJOCHA et al., "Development of a Monoctonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," The J. of Nuclear Med. 33:2184-2189 (1992). MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," Proc. Natl. Acad. Sci. USA, 82:4245-4249 (1985). MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," J. Micro. Encap., 14(2): 197-210 (1997). MEDA et al., "Activation of microglial cells by β-amyloid protein and interferon-γ," Nature, 374:647-650 (1995). MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J. Exp. Med., 174:791-798 (1991). MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," J. Biol. Chem., 267(24):17082-17088 (1992). MURPHY et al., "Development of a Monoctonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994).	
218 MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," The J. of Nuclear Med. 33:2184-2189 (1992). 217 MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," Proc. Natl. Acad. Sci. USA 82:4245-4249 (1985). 328 MCGEE et al., "The encapsulation of a model protein in poly (D. L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," J. Micro. Encap., 14(2): 197-210 (1997). 329 MEDA et al., "Activation of microglial cells by β-amyloid protein and interferon-γ," Nature, 374:647-650 (1995). 330 MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J. Exp. Med., 174:791-798 (1991). 331 MILLER et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," J. Biol. Chem., 267(24):17082-17088 (1992). 332 MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994).	-
Application to In Vitro Imaging of Amyloid Angiopathy," The J. of Nuclear Med. 33:2184-2189 (1992). 217 MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," Proc. Natl. Acad. Sci. USA, 82:4245-4249 (1985). 318 MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," J. Micro. Encap., 14(2): 197-210 (1997). 319 MEDA et al., "Activation of microglial cells by β-emyloid protein and interferon-γ," Nature, 374:647-650 (1995). 320 MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J. Exp. Med., 174:791-798 (1991). 321 MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," J. Biol. Chem., 267(24):17082-17088 (1992). 322 MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994). 323 NATHANSON et al. "Rovine Spanniform Encephalopathy (BSE): Causes and Consequences of a Common Source.	
USA, 82:4245-4249 (1985). MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," J. Micro. Encap., 14(2): 197-210 (1997). MEDA et al., "Activation of microglial cells by β-amyloid protein and interferon-γ," Nature, 374:647-650 (1995). MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J. Exp. Med., 174:791-798 (1991). MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," J. Biol. Chem., 267(24):17082-17088 (1992). MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and fts Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994).	
sizes: an evaluation of process reproducibility," J. Micro. Encap., 14(2): 197-210 (1997). MEDA et al., "Activation of microglial cells by β-amyloid protein and interferon-γ," Nature, 374:647-650 (1995). MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J. Exp. Med., 174:791-798 (1991). MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," J. Biol. Chem., 267(24):17082-17088 (1992). MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994).	
MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J. Exp. Med., 174:791-798 (1991). MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," J. Biol. Chem., 287(24):17082-17088 (1992). MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and (ts Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994).	긥
798 (1991). 206 MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimar's Disease," J. Biol. Chem 287(24):17082-17088 (1992). 191 MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994).	
267(24):17082-17088 (1992). MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and its immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994).	
191 Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994). NATHANSON et al. "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source.	
NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic." Am. J. Epidemiol., 145(11): 959-969 (June 1, 1997).	
	_
New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).	7
PARESCE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," Neuron, 17:553-565 (September 1996).	_
PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers," <u>Eur. J. Immunol.</u> , 25: 3521-3524 (1995).	_
PRIEELS et al., "Synergistic adjuvants for vaccines," Chemical Abstracts, 120(8): pg. 652, column 1, abstract 86406t (1994).	_
COU 143 QUON et al., "Formation of β-Amyloid protein deposits in brains of transgenic mice," Nature, 352:239-241 (1991).	_
144 PAGE, V.A., Crent application # + Ft+9 AGI 5746 01, (publication date unknown)	

Examiner	Milli on	Date	11/15/02
Signature	V. That the	Considered	11/3/02

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

TECH CENTER 1600/2900

Approved for use through 10/31/2002. OMB 0651-0031*
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

C mplete if Known Substitute for form 1449A/PTO **Application Number** 09/724,953 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT Schenk, Dale B. First Named Inventor 1647 Group Art Unit (use as many sheets as necessary) **Examiner Name** Unassigned <u>Nichds</u> Attorney Docket Number 15270J-005913US

118	\geq		
رجي	C72 5	RASO, "Immunotherapy of Alzheimer's Disease," Immunotherapy Weekly. Abstract (April 2, 1998).	
	FIGE	ROGERS et al., "Complement activation by β-amyloid in Alzheimer Disease," PNAS, 89:1-5 (1992).	
BADOMAS	147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," Annals of New York <u>Academy of Sciences</u> , 695:198-202 (1993).	
دى	209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide</u> <u>Hormones,</u> J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976).	
C82	189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993).	
430	194	SAIDO et al., "Spatial Resolution of the Primary β-Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J.</u> <u>Biol. Chem.</u> , 269(21):15253-15257 (1994).	
حيى	178	SCHENK et al., "Therapeutic Approaches Related to Amyloid-β Peptide and Alzheimer's Disease," <u>J. Med. Chem.,</u> 38(21):4141-4154 (1995).	
دص	148	SCHENK et al., "Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).	
رى	149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," Nat. Biotech., 18:823-824 (2000).	
භ	150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," J. Neuropathol. Exp. Neurol., 53(5): 438-447 (1994).	
COV	151	SELKOE, "Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease." Trends in Neurosciences, 16(10): 403-409 (1993).	_
Con	152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease," <u>Scientific American</u> , pgs. 68-78 (November, 1991).	
CON	153	SELKOE, Dennis J., "In the Beginning," <u>Nature</u> , 354:432-433 (1991).	
دهه	154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease." Neuron, 6:487-498 (1991).	
SON	155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," Science, 275:630-631 (1997).	
ري	156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992).	
(2)	157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," Neuroscience Res., 13:237-255 (1992).	
50	158	SMITS et al., "Prion Protein and Scrapie Susceptibility," Vet. Quart., 19(3): 101-105 (1997).	
	\$ 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	209 (S) 209 (S) 189 (S) 194 (S) 178 (S) 148 (S) 149 (S) 150 (S) 151 (S) 152 (S) 153 (S) 154 (S) 155 (S) 156 (S) 157	ROGERS et al., "Complement activation by β-amyloid in Alzheimer Disease." PNAS, 89:1-5 (1992). ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," Annals of New York Academy of Sciences, 695:188-202 (1993). RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in Peptide Hormones, J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976). SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," J. Biol. Chem., 288(33):25239-25243 (1993). SAIDO et al., "Spatial Resolution of the Primary β-Amyloidopenic Process Induced in Postischemic Hippocampus." J. Biol. Chem., 289(21):15253-15257 (1994). SCHENK et al., "Therapeutic Approaches Related to Amyloid-β Peptide and Alzheimer's Disease." J. Med. Chem., 38(21):414-14154 (1995). SCHENK et al., "Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse." Nature, 400:173-177 (1998). SELKOE, D.J., "Imaging Alzheimer's Amyloid," Nat. Biotech., 18:823-824 (2000). SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," Nat. Biotech., 18:823-824 (2000). SELKOE, "Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease," Trends in Neurosciences, 18(10): 403-409 (1993). SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease", "Scientific American, pgs. 68-78 (November, 1991). SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease", Scientific American, pgs. 68-78 (November, 1991). SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," Science, 275:630-631 (1997). SEURGER Tet al., "isolation and quantification of soluble Alzheimer's Disease." Neuroscience Res., 13:237-255 (1992).

		<u> </u>		
Examiner Signature	Collin	165	Date Considered	11/15/02

EXAMINER: Initial if eference considered, whether or not eliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3173244 v1

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO Complete if Kn wn Application Number 09/724,953 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT Schenk, Dale B. First Named Inventor Group Art Unit 1647 (use as many sheets as necessary) Examiner Name Unassigned Nichols Sheet of 10 15270J-005913US

Attorney Docket Number

POSON	159	SOLOMON et al., "Disaggregation of Alzheimer β-amyloid by site-directed mAb," PNAS, 94:4109-4112 (1997).	
30	160	SOLOMON et al., "Monoclonal antibodies inhibit in <i>vitro</i> fibrillar aggregation of the Alzheimer β-amyloid peptide," <u>PNAS</u> , 93:452-455 (1996).	
0 3 2000	101	SOLOMON, A., "Pro-Po-(Fretein Therepoullus), "University of Tennessee Medical Center (publication date unknown)."	
RADEMARKO	162	SQLOMON, B., "New Approach Towards Feet Induction of Anti & Amyleid Reptide Immune Response," Department of Malecular Microbiology & Biotochnology, Tel Aviv University, Remet Aviv, 1st Aviv, 1stact (publication date-	
620	182	SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's β-amyloid peptide aggregation," Int. J. Exp. Clin. Invest., 3:130-133 (1996).	
حوص	184	SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," Biochem. Mol. Biol. Int., 43(3):601-611 (1997).	
ري	185	SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1996).	
	186	SOLOMONI et al., "Activity of manacional antibodies in prevention of in vitro aggregation of their entigene," obstract from Department of Molecular Microbiology and Sintechnology. Tel Aviv University, Tel Aviv, Israel (publication date	
SSS	179	SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzhelmer's Disease," J. Neurochemistry, 66:259-265 (1996).	_
90	163	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum</i> Malaria", <u>N. Engl. J. Med.,</u> 336(2): 86-91 (1997).	
627	164	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <u>PNAS</u> , 94: 13287-13292 (1997).	
572	165 .	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats." <u>European J. Pharmacology</u> , 352:135-142 (1998).	
حص	166	TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," Immunobiology , 191(2-3):114-115 Abstract C.37, (1994).	
(37)	167	VAN GOOL et al., "Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," Neuroscience Letters. 172:122-124 (1994).	
حص	168	VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <u>Amer. Journ. Pathology</u> , 144(1):104-116 (1994).	
WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <u>J. Neuropath. Exp. Neuropath. 53(4):377-383 (1994).</u>		WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <u>J. Neuropath. Exp. Neurology,</u> 53(4):377-383 (1994).	
C3V	180	WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ- Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu. Rev. Immunol.</u> , 12:809-837 (1994).	
(D)	170	WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," Curr. Opin, Neurobiol., 7: 695-700 (1997).	

Examiner Signature	Elling.	Date Considered	11/15/02
Olginature	CACIII III	Considered	11/19/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include capy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3173244 v1

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box

OCT 0 3 200

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

spond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, n & TR.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(DOC GO INGIN	0,,00,00	,
Shoot 10	of	140

EMARK	Complete if Known	
Application Number	09/724,953	
Filing Date	November 28, 2000	
First Named Inventor	Schenk, Dale B.	
Group Art Unit	1647	
Examiner Name	Unassigned Dichols	
Attorney Docket Number	15270J-005913US	

دي	171	WEN, G.Y., "Alzheimer's Disease and Risk Factors." J. Food Drug Analysis, 6(2):465-476 (1998).	
حص	172	WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," Nature Biotech., 18:868-824 (2000).	
(4)	219	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," Proc. Natl. Acad. Sci. USA, 82:8729-8732 (1985).	
COU	173	WOOD et al., "Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease," PNAS, 94: 1550-1555 (1997).	
20	174	Human Immunology & Sensor Program brochure, from The University of Tonescoo Medical Center/ Graduate School of Medicine, Knowillo, Tennescoo (publication date enknown)	

CONSIDEREDIDO NOT PRINT (NO DATE).

Date Examiner Considered Signature

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Inclide copy of this form with next communication to applicant.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3173244 v1

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Dale B. Schenk

Application No.: 09/585,817

Page 2



FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document		No (Detector	Date of Publication of	Pages, Columns, Lines,		
		Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ⁶
	AU							
	AV			·				
	AW							
	AX							
	AY							
	AZ							
	BA							
_	BB						'	

Examiner Signature	6 Miles	Date Considered	263/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

PA 3172864 v1

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.